LGP2 Activators
The chemical class known as LGP2 activators comprises a diverse range of compounds that exert their influence on the expression and activity of the Laboratory of Genetics and Physiology 2 (LGP2) protein through specific biochemical and cellular pathways. LGP2 is a crucial component of the innate immune system, involved in the recognition of viral nucleic acids. While no direct activators are identified, these compounds function indirectly by modulating pathways associated with viral recognition and antiviral responses. One group of LGP2 activators includes viral RNA mimetics such as Poly(I:C), Poly(U), and 2-Aminopurine. These compounds activate the RIG-I pathway by mimicking viral RNA structures, leading to increased expression and activity of LGP2. Another set, including Ribavirin and Ribocil, induces cellular stress and alters RNA secondary structure, respectively, resulting in the activation of LGP2 through the RIG-I pathway. These examples highlight the importance of specific RNA structural features and cellular stress responses in LGP2 activation.
Chloroquine and Ammonium chloride act as indirect LGP2 activators by inhibiting endosomal acidification. This alteration in endosomal pH activates the RIG-I pathway, subsequently increasing LGP2 expression and activity. Additionally, Poly(dA:dT) and Enadenotucirev (EnAd) activate LGP2 indirectly through the cGAS-STING pathway, illustrating the diverse pathways that converge on LGP2 activation. Notably, compounds like Imiquimod and VX-765 influence LGP2 expression and activity through the TLR7 and caspase-1 pathways, respectively. Imiquimod stimulates TLR7, leading to downstream activation of LGP2, while VX-765 inhibits caspase-1, resulting in the activation of the STING pathway and subsequent upregulation of LGP2. These examples underline the intricate interplay between different immune pathways and LGP2 activation. In summary, the chemical class of LGP2 activators comprises compounds that modulate specific pathways associated with viral recognition and antiviral responses. By understanding the diverse mechanisms through which these activators influence LGP2, we gain insights into the complex network of immune signaling pathways orchestrating the innate immune response against viral infections.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod is an indirect LGP2 activator that stimulates the TLR7 pathway. Activation of TLR7 induces downstream signaling events that lead to increased expression and activity of LGP2, showcasing the specific immune pathway through which Imiquimod influences LGP2 activation. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Poly(I:C) is an indirect LGP2 activator that mimics viral dsRNA and activates the RIG-I pathway. RIG-I activation subsequently upregulates LGP2 expression, illustrating the specific antiviral pathway through which Poly(I:C) influences LGP2 activation. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Ribavirin serves as an indirect LGP2 activator by promoting RNA virus-induced stress. The antiviral activity of Ribavirin results in increased viral RNA production, leading to the activation of LGP2 as part of the cellular response to viral infection. This demonstrates the specific cellular stress pathway through which Ribavirin influences LGP2 activation. | ||||||
Polyuridylic acid potassium salt | 27416-86-0 | sc-215733 sc-215733A | 10 mg 25 mg | $189.00 $343.00 | 2 | |
Poly(U) is an indirect LGP2 activator that mimics viral RNA and activates the RIG-I pathway. Activation of RIG-I leads to increased expression and activity of LGP2, illustrating the specific antiviral pathway through which Poly(U) influences LGP2 activation. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine serves as an indirect LGP2 activator by inhibiting endosomal acidification. The resulting alteration in endosomal pH activates the RIG-I pathway, leading to increased LGP2 expression and activity. This highlights the specific cellular process through which Chloroquine influences LGP2 activation. | ||||||
2-Aminopurine | 452-06-2 | sc-287828 sc-287828A | 100 mg 250 mg | $118.00 $185.00 | ||
2-Aminopurine is an indirect LGP2 activator that mimics viral RNA and activates the RIG-I pathway. Activation of RIG-I subsequently upregulates LGP2 expression, showcasing the specific structural features of RNA analogs that influence LGP2 activation. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
This solution is an indirect LGP2 activator that inhibits endosomal acidification. The resulting change in endosomal pH activates the RIG-I pathway, leading to increased LGP2 expression and activity. This demonstrates the specific cellular process through which Ammonium chloride influences LGP2 activation. | ||||||
VX-765 | 273404-37-8 | sc-475845 sc-475845A sc-475845B | 5 mg 10 mg 50 mg | $228.00 $302.00 $968.00 | 1 | |
VX-765 is an indirect LGP2 activator that inhibits caspase-1. Caspase-1 inhibition results in the activation of the STING pathway, leading to increased LGP2 expression and activity. This demonstrates the specific cellular process through which VX-765 influences LGP2 activation. | ||||||